KEL1 negative red cell transfusions for females of current or future child‐bearing potential: A clinical impact and feasibility study.

Background: Anti‐K is an alloantibody stimulated in response to the KEL1 antigen and may cause hemolytic disease of the fetus and newborn (HDFN). Provision of KEL1 negative blood to females of child‐bearing potential was not our practice. We assessed the impact of our policy and assessed feasibility of a KEL1 negative transfusion policy. Study design and methods: This is a cohort study spanning Jan 1, 2007–Jun 30, 2017 in Hamilton, Canada. Data were obtained via our institution's transfusion database. Chart reviews of females age ≤45 with anti‐K were performed; data on RBC KEL1 phenotype were obtained from the blood supplier when needed to ascertain the cause of alloimmunization. Descriptive analysis of hospital KEL1 negative inventory demand and supply was performed. Results: From Jan 2007‐Jun 2017, 8.6% of all RBC units transfused were provided to females age ≤45. There were 111 females with detectable anti‐K. Median age at time of antibody detection was 34 years (interquartile range 27–40) and 28 of 111 (25.2%) patients may have been alloimmunized by transfusion. Of 49 pregnancies, seven had complications due to anti‐K. We estimated that our existing RBC inventory (with 16% units known to be KEL1 negative in 2017) is sufficient to meet demand and support a KEL1 negative transfusion policy for females age ≤45. Conclusion: Transfusion was responsible for alloimmunization in 25% of females with anti‐K over 10 years. Analysis of supply and demand can be used to inform feasibility of a KEL1 negative transfusion policy. [ABSTRACT FROM AUTHOR]

Copyright of Transfusion is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)